The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.

The receptor activator of nuclear factor-?B (RANK) and its ligand RANKL are members of the tumor necrosis factor (TNF) super-family of cytokines with a role in progestogen-associated malignancies in breast. Basic and clinical data support the participation of the cytokine pathway in metastatic disea...

Full description

Bibliographic Details
Authors: Monzo-Miralles, Ana, Martin-Gonzalez, Victor, Smith-Ballester, Sara, Iglesias-Miguel, Victoria, Cano, Antonio
Format: article
Status:Published version
Publication Date:2021
Country:España
Institution:INCLIVA
Repository:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p15882
Online Access:https://incliva.portalinvestigacion.com/publicaciones/15882
Access Level:Open access
Keyword:RANK
RANKL
breast
cancer
genital tract
id ES_b138ce7eaee2d2d9ebda415d0c81c233
oai_identifier_str oai:incliva.fundanetsuite.com:p15882
network_acronym_str ES
network_name_str España
repository_id_str
spelling The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.Monzo-Miralles, AnaMartin-Gonzalez, VictorSmith-Ballester, SaraIglesias-Miguel, VictoriaCano, AntonioRANKRANKLbreastcancergenital tractThe receptor activator of nuclear factor-?B (RANK) and its ligand RANKL are members of the tumor necrosis factor (TNF) super-family of cytokines with a role in progestogen-associated malignancies in breast. Basic and clinical data support the participation of the cytokine pathway in metastatic disease and as poor prognosis markers. The value of RANK/RANKL as prognostic indicators in endometrial and ovarian tumors, as well as the data suggesting a potential role of RANK/RANKL in hormone dependent tumorigenesis in the endometrium, have been described. The D-CARE study could not confirm benefit in the modulation of RANKL in breast cancer.WROCLAW MEDICAL UNIV2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/15882Advances in Clinical and Experimental MedicineISSN: 18995276ISSNe: 24512680reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p158822026-06-07T16:35:31Z
dc.title.none.fl_str_mv The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
title The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
spellingShingle The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
Monzo-Miralles, Ana
RANK
RANKL
breast
cancer
genital tract
title_short The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
title_full The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
title_fullStr The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
title_full_unstemmed The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
title_sort The RANKL/RANK system in female reproductive organ tumors: A preclinical and clinical overview.
dc.creator.none.fl_str_mv Monzo-Miralles, Ana
Martin-Gonzalez, Victor
Smith-Ballester, Sara
Iglesias-Miguel, Victoria
Cano, Antonio
author Monzo-Miralles, Ana
author_facet Monzo-Miralles, Ana
Martin-Gonzalez, Victor
Smith-Ballester, Sara
Iglesias-Miguel, Victoria
Cano, Antonio
author_role author
author2 Martin-Gonzalez, Victor
Smith-Ballester, Sara
Iglesias-Miguel, Victoria
Cano, Antonio
author2_role author
author
author
author
dc.subject.none.fl_str_mv RANK
RANKL
breast
cancer
genital tract
topic RANK
RANKL
breast
cancer
genital tract
description The receptor activator of nuclear factor-?B (RANK) and its ligand RANKL are members of the tumor necrosis factor (TNF) super-family of cytokines with a role in progestogen-associated malignancies in breast. Basic and clinical data support the participation of the cytokine pathway in metastatic disease and as poor prognosis markers. The value of RANK/RANKL as prognostic indicators in endometrial and ovarian tumors, as well as the data suggesting a potential role of RANK/RANKL in hormone dependent tumorigenesis in the endometrium, have been described. The D-CARE study could not confirm benefit in the modulation of RANKL in breast cancer.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/15882
url https://incliva.portalinvestigacion.com/publicaciones/15882
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WROCLAW MEDICAL UNIV
publisher.none.fl_str_mv WROCLAW MEDICAL UNIV
dc.source.none.fl_str_mv Advances in Clinical and Experimental Medicine
ISSN: 18995276
ISSNe: 24512680
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416911881633792
score 15,812455

Similar Items